Spots Global Cancer Trial Database for Phase I/II Study of hLL1 in Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I/II Study of hLL1 in Multiple Myeloma
Official Title: A Phase I/II Study of Immunotherapy With hLL1 Administered Twice Weekly for 4 Consecutive Weeks in Patients With Multiple Myeloma
Study ID: NCT00421525
Interventions
Study Description
Brief Summary: This is a Phase I/II, open-label, multi-center study conducted in patients with recurrent or refractory multiple myeloma who have failed at least two prior standard systemic treatments.
Detailed Description: All patients receive hLL1 administered intravenously twice weekly for 4 consecutive weeks. Cohorts of 3-6 patients will receive escalating doses of hLL1 in order to determine the maximum tolerated dose (MTD) for this administration schedule. Up to approximately 30 additional patients will be entered at one or more dose levels at or below the MTD in order to determine the optimal dose for subsequent studies.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
Center for Cancer Care, Goshen, Indiana, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
New York Presbyterian Hospital/Cornell Medical Center, New York, New York, United States
Hospital University of Pennsylvania, Philadelphia, Pennsylvania, United States
Contact Details
Name: William Wegener, MD, PhD
Affiliation: Gilead Sciences
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
